Tirzepatide in HFpEF with obesity (SUMMIT)

Evidence tier

Emerging / Investigational · Dual / triple agonist · CKM

Plain-language summary

The dual GIP/GLP-1 agonist tirzepatide improved heart-failure outcomes and symptoms in HFpEF with obesity — a single positive trial on a cardiac endpoint, included here as it extends the CKM story to the heart; renal outcomes were not assessed.

Key findings

Improved heart-failure outcomes and symptom/functional measures vs placebo in HFpEF with obesity.

Population

Adults with HFpEF and obesity; tirzepatide vs placebo.

What this does not prove

Cardiac, not renal, endpoint; single trial. Does not establish nephroprotection.

Primary source

Packer M, et al. N Engl J Med. 2024.
https://www.nejm.org/doi/full/10.1056/NEJMoa2410027

Educational only

Paraphrased from the primary publication; not individual medical advice. Verify against the source before applying to care.